Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study (ARPO)

Bart Rijnders

Status: Enrolling

Conditions: Invasive Aspergillosis

Treatments: Diagnostic Test: Aspergillus PCR

Study type: Observational

Funder types: Other

Identifiers

NCT06069505

MEC-2017-391 (Other Identifier)

NL62004.078.17

Details and patient eligibility

About

Invasive aspergillosis (IA) is the most common mould infection in immunocompromised patients with haematological disease. Voriconazole, a triazole, improves overall survival of patients with an IA and is the mainstay of therapy. Resistance of A. Fumigatus emerged as an important clinical problem and infections with azole resistant Aspergillus have a high mortality. Nowhere in the world, azole resistance is more prevalent than in the Netherlands. Rapid detection of resistance is key to improve the patient's outcome but fungal cultures take time and are often negative. The investigators aim to detect azole resistance associated mutations in fungal DNA extracted directly from serum or plasma to accelerate diagnosis and improve outcome of patients infected with azole resistant A. fumigatus.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years or older.
• Lung CT shows lesions that fulfil the EORTC/MSG radiological criteria of possible invasive fungal infection.
• A bronchoalveolar lavage is planned or has been performed <48hrs earlier

Exclusion criteria

• Patients unable or unwilling to provide consent